Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
hormones are intact or properly replaced (4, 5, 6) . In addition, GH replacement in these subjects has been shown to reverse many of the abnormalities (7) . There is a paucity of data on recombinant human GH (r-hGH) replacement therapy in acromegaly
Search for other papers by Adriano N Cury in
Google Scholar
PubMed
Search for other papers by Verônica T Meira in
Google Scholar
PubMed
Pediatric Endocrinology Unit, Endocrinology and Metabolism, Nuclear Medicine Laboratory, Pediatrics Department, Irmandade da Santa Casa de Misericórdia de São Paulo, 01221-020 São Paulo, Brazil
Search for other papers by Osmar Monte in
Google Scholar
PubMed
Search for other papers by Marília Marone in
Google Scholar
PubMed
Search for other papers by Nilza M Scalissi in
Google Scholar
PubMed
Search for other papers by Cristiane Kochi in
Google Scholar
PubMed
Search for other papers by Luís E P Calliari in
Google Scholar
PubMed
Search for other papers by Carlos A Longui in
Google Scholar
PubMed
(before, during, and after RAI treatment), ATDs that were given before RAI therapy, hormone concentrations, and imaging, such as ultrasonography and thyroid scan radioiodine uptake. Other data that were related to RAI therapy were total iodine dose, number
Search for other papers by Lauren R Cirrincione in
Google Scholar
PubMed
Search for other papers by Bridgit O Crews in
Google Scholar
PubMed
Search for other papers by Jane A Dickerson in
Google Scholar
PubMed
Search for other papers by Matthew D Krasowski in
Google Scholar
PubMed
Search for other papers by Jessica Rongitsch in
Google Scholar
PubMed
Search for other papers by Katherine L Imborek in
Google Scholar
PubMed
CUNY Graduate School of Public Health and Health Policy, New York, New York, USA
Search for other papers by Zil Goldstein in
Google Scholar
PubMed
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
Search for other papers by Dina N Greene in
Google Scholar
PubMed
Introduction Estradiol (17β-estradiol) is a natural sex steroid available in several exogenous preparations. The Endocrine Society recommended high-dose exogenous estradiol treatment as one part of feminizing hormone therapy for transgender
Search for other papers by David S McLaren in
Google Scholar
PubMed
Search for other papers by Aarani Devi in
Google Scholar
PubMed
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
the use of proton therapy for the treatment of medulloblastoma has reduced the incidence of primary hypothyroidism, sex hormone deficiency, and the need for any hormone replacement therapy ( 51 , 52 ). One study reported that those treated with
Search for other papers by Marcus Quinkler in
Google Scholar
PubMed
Search for other papers by Bertil Ekman in
Google Scholar
PubMed
Search for other papers by Claudio Marelli in
Google Scholar
PubMed
Search for other papers by Sharif Uddin in
Google Scholar
PubMed
Search for other papers by Pierre Zelissen in
Google Scholar
PubMed
Search for other papers by Robert D Murray in
Google Scholar
PubMed
Search for other papers by on behalf of the EU-AIR Investigators in
Google Scholar
PubMed
cortisone, resulting in higher systemic availability of the active 11β-hydroxy form, prednisolone ( 12 ). Prednisolone is used in some patients with adrenal insufficiency (AI) as hormone replacement therapy. Advocates of prednisolone highlight that it
Search for other papers by Kazhan Mollazadegan in
Google Scholar
PubMed
Search for other papers by Britt Skogseid in
Google Scholar
PubMed
Search for other papers by Johan Botling in
Google Scholar
PubMed
Search for other papers by Tobias Åkerström in
Google Scholar
PubMed
Search for other papers by Barbro Eriksson in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Anders Sundin in
Google Scholar
PubMed
Search for other papers by Joakim Crona in
Google Scholar
PubMed
demonstrated longer survival for panNET-G3 (range, 41–42 months) than for panNEC (range, 9–17 months) ( 8 , 9 ). Moreover, it has been hypothesized that panNET-G3 and panNEC respond differently to systemic therapy, with higher response rates on platinum
Search for other papers by Hyun-Ah Kim in
Google Scholar
PubMed
Search for other papers by Jihye Choi in
Google Scholar
PubMed
Search for other papers by Chan Sub Park in
Google Scholar
PubMed
Search for other papers by Min-Ki Seong in
Google Scholar
PubMed
Search for other papers by Sung-Eun Hong in
Google Scholar
PubMed
Search for other papers by Jae-Sung Kim in
Google Scholar
PubMed
Search for other papers by In-Chul Park in
Google Scholar
PubMed
Search for other papers by Jin Kyung Lee in
Google Scholar
PubMed
Search for other papers by Woo Chul Noh in
Google Scholar
PubMed
Search for other papers by the ASTRRA trial investigators in
Google Scholar
PubMed
/m 2 ) q3w or four cycles of (doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 ) q3w followed by four cycles of (docetaxel 100 mg/m 2 ) q3w or six cycles of (doxorubicin 50 mg/m 2 and docetaxel 75 mg/m 2 ) q3w. For adjuvant hormone therapy, all
Search for other papers by Nadia Sawicka-Gutaj in
Google Scholar
PubMed
Search for other papers by Ariadna Zybek-Kocik in
Google Scholar
PubMed
Search for other papers by Michał Kloska in
Google Scholar
PubMed
Search for other papers by Paulina Ziółkowska in
Google Scholar
PubMed
Search for other papers by Agata Czarnywojtek in
Google Scholar
PubMed
Search for other papers by Jerzy Sowiński in
Google Scholar
PubMed
Search for other papers by Dorota Mańkowska-Wierzbicka in
Google Scholar
PubMed
Search for other papers by Marek Ruchała in
Google Scholar
PubMed
total fat mass and insulin were mediators. P value <0.05 was considered statistically significant. Results Effects of therapy on hormonal and metabolic status Hormonal and metabolic parameters are compared in Table 1 . Table 1
Search for other papers by Anita Hokken-Koelega in
Google Scholar
PubMed
Search for other papers by Aart-Jan van der Lely in
Google Scholar
PubMed
Search for other papers by Berthold Hauffa in
Google Scholar
PubMed
Search for other papers by Gabriele Häusler in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Mohamad Maghnie in
Google Scholar
PubMed
Search for other papers by Jesús Argente in
Google Scholar
PubMed
Search for other papers by Jean DeSchepper in
Google Scholar
PubMed
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by John W Gregory in
Google Scholar
PubMed
Search for other papers by Charlotte Höybye in
Google Scholar
PubMed
Search for other papers by Fahrettin Keleştimur in
Google Scholar
PubMed
Search for other papers by Anton Luger in
Google Scholar
PubMed
Search for other papers by Hermann L Müller in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Vera Popovic-Brkic in
Google Scholar
PubMed
Search for other papers by Eleonora Porcu in
Google Scholar
PubMed
Search for other papers by Lars Sävendahl in
Google Scholar
PubMed
Search for other papers by Stephen Shalet in
Google Scholar
PubMed
Search for other papers by Bessie Spiliotis in
Google Scholar
PubMed
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
hormone therapy, at supraphysiological doses, can improve adult height (gain of approximately 8 cm) with early treatment, preventing short stature in the majority of patients. Improvement in adult height is superior when administered earlier rather than
Search for other papers by Ditte Sofie Dahl Sørensen in
Google Scholar
PubMed
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
-hydroxyprogesterone in the upper normal to mildly elevated normal range as a treatment goal ( 3 ), but currently, there is no consensus in relation to optimal disease markers or timing between replacement therapy and assessment of hormone levels. In the guideline by